Artelo Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Artelo Biosciences şirketinin toplam hissedar öz sermayesi $6.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $7.1M ve $775.0K dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$4.86m
Eşitlik	US$6.36m
Toplam yükümlülükler	US$775.00k
Toplam varlıklar	US$7.14m

Son finansal sağlık güncellemeleri

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Mar 28

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Nov 02

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

May 20

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Feb 04

Recent updates

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Aug 16

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Mar 28

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

May 20

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Feb 04

INO, VXRT, BTU and TTM among premarket gainers

Feb 02

Artelo Biosciences EPS misses by $0.04

Jan 14

Artelo Biosciences on go with cancer appetite recovery study

Nov 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ARTL 'nin kısa vadeli varlıkları ( $5.0M ) kısa vadeli yükümlülüklerini ( $697.0K ) aşıyor.

Uzun Vadeli Yükümlülükler: ARTL şirketinin kısa vadeli varlıkları ( $5.0M ) uzun vadeli yükümlülüklerini ( $78.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ARTL borçsuzdur.

Borcun Azaltılması: ARTL un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ARTL şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: ARTL un, serbest nakit akışı her yıl % 18.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Artelo Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Recent updates

New minor risk - Share price stability

Artelo Biosciences, Inc., Annual General Meeting, Dec 20, 2024

Artelo Biosciences, Inc. Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program

Insufficient new directors

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12

Artelo Biosciences, Inc. Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium

Artelo Biosciences, Inc. Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform

New major risk - Revenue and earnings growth

New major risk - Financial position

Artelo Biosciences, Inc. Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Artelo Biosciences, Inc. Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023

New major risk - Revenue and earnings growth

Artelo Biosciences Selects for Oral Presentation to Report Positive Research Findings on Art12.11

Artelo Biosciences, Inc., Annual General Meeting, Jun 30, 2023

Price target decreased by 16% to US$35.00

Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Price target increased to US$57.50

Artelo Biosciences, Inc. Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13

Artelo Biosciences, Inc., Annual General Meeting, Jun 24, 2022

Price target decreased to US$4.08

High number of new directors

Artelo Biosciences, Inc. Reports Positive Pre-Clinical Results for Lead Program in Cancer-Related Cachexia

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Artelo Biosciences, Inc. Anticipates Accelerated Clinical Development for ART27.13

High number of new directors

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

Independent Director John Beck has left the company

Relief For Cancer Patients In Artelo Bioscience Pipeline

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences, Inc. Appoints Tamara A. Seymour to its Board of Directors

Artelo Biosciences, Inc. Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal

New 90-day high: US$1.28

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Artelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia

INO, VXRT, BTU and TTM among premarket gainers

Artelo Biosciences EPS misses by $0.04

New 90-day high: US$1.00

Artelo Biosciences, Inc. Appoints Gregory R. Reyes to the Company’s Board of Directors

Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss

Artelo Biosciences on go with cancer appetite recovery study

New 90-day low: US$0.65

Artelo Biosciences, Inc. has completed a Composite Units Offering in the amount of $6.6 million.

Artelo Biosciences, Inc. Receives Ethics Approval to Commence Its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia

New 90-day low: US$0.71

New 90-day low - US$0.94

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin